1stOncology™: Cancer Intelligence Service – Page 12518 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Getinge Full Year Report 2019: Continued Growth, Higher Margins and Strengthened Cash Flow

On January 30, 2020 Getinge reported Our organic sales growth continued in the fourth quarter and it was particularly good to see the strong performance of our three largest markets – the US, China and Germany," says Mattias Perjos, President & CEO (Press release, Getinge, JAN 30, 2020, View Source [SID1234553730]). "We improved the margins and the cash flow both in the quarter and for the full year, and the balance sheet was strengthened."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The order intake for the business area Surgical Workflows was slightly lower than Q4 2018, mainly related to the weak start to the quarter in Americas and APAC. The quarter ended on a strong note for Getinge and total order bookings were better than at the end of 2018. In 2020 net sales is expected to increase organically by 2-4%.

The gross margin for the quarter was positively impacted by a favorable sales mix, higher productivity and currency effects.

"This has contributed to a strengthened operating margin year-on-year. It is positive that we are starting to see the results of our focused efforts and we are now entering 2020 with continuous focus on strengthening the business and on creating increased value for our customers", says Mattias Perjos.

October – December 2019 in brief

Net sales increased by 1.8% organically and the order intake rose by 0.9% organically.
Adjusted gross profit amounted to SEK 4,304 M (3,790) and the margin was 50.6% (48.0). IFRS 16 had a positive effect of SEK 31 M on adjusted gross profit.
Adjusted EBITA amounted to SEK 1,673 M (1,412) and the adjusted EBITA margin was 19.7% (17.9). IFRS 16 had a positive effect of SEK 4 M on adjusted EBITA.
Adjusted earnings per share amounted to SEK 3.84 (3.47). The effect of IFRS 16 was SEK -0.01 per share.
The acquisition of Applikon Biotechnology B.V. – a leading company in advanced bioreactor systems for biopharmaceutical research and production – was completed after the end of the reporting period (January 3, 2020).
January – December 2019 in brief

Net sales increased by 3.9% organically and the order intake rose by 4.1% organically.
Adjusted gross profit amounted to SEK 13,401 M (11,943) and the margin was 50.5% (49.4). IFRS 16 had a positive effect of SEK 116 M on adjusted gross profit.
Adjusted EBITA amounted to SEK 3,310 M (2,689) and the adjusted EBITA margin was 12.5% (11.1). IFRS 16 had a positive effect of SEK 13 M on adjusted EBITA.
Adjusted earnings per share amounted to SEK 7.02 (5.91). The effect of IFRS 16 was SEK -0.03 per share.
A dividend per share of SEK 1.50 (1.00) is proposed, which amounts to SEK 409 M (272).
Teleconference

A conference call will be held on January 30, 2020 at 10.00-11.00 a.m. CET hosted by Mattias Perjos, President & CEO and Lars Sandström, CFO.

Isofol Medical: The Phase 1/2a Study ISO-CC-005 is Completed

On January 30, 2020 Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), reported that the recruitment and treatment of patients in the company’s Phase 1/2a study with arfolitixorin has been completed (Press release, Isofol Medical, JAN 30, 2020, View Source [SID1234553729]). Totally 101 patients have been treated at 10 hospitals in the Nordic countries and Europe. The final analysis has started and study data is expected to be presented at ESMO (Free ESMO Whitepaper) 2020.

Ulf Jungnelius, M.D., Chief Executive Officer of Isofol, comments: "ISO-CC-005 has fulfilled its purpose by determining the dose we have chosen for further development in our Global Phase 3 AGENT study. Our focus now is taking the AGENT study in goal and submitting the results for a market approval. "

Isofol’s target with the ISO-CC-005 study was to develop an effective and safe dose of arfolitixorin for continued clinical development. An expanded patient group to determine the safety profile of arfolitixorin in combination with the today’s standard of care in first-line metastatic colorectal cancer, has now been conducted in accordance with protocol and the study has fulfilled its purpose and concluded.

The information was submitted for publication, through the agency of the contact person set out above, at 08:15 CET on January 30, 2020.

About arfolitixorin

Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase 3 study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.

Medivir has Received Notices of Allowance in the EU and Japan for MIV-818 Patent Applications

On January 30, 2020 Medivir AB (Nasdaq Stockholm: MVIR) reports that the MIV-818 patent portfolio has been reinforced by the issue of notices of allowance from the European Patent Office and the Japanese Patent Office for the MIV-818 composition-of-matter and liver cancer treatment claims (Press release, Medivir, JAN 30, 2020, View Source [SID1234553728]).

Corresponding notices of allowance or patent grants have already been issued in USA, Australia, Indonesia, Israel, Philippines, Russia, Singapore and South Africa. Applications are pending in a large number of other countries in Asia and around the world. The patents will be in force until August 2035.

– "It is comforting that our lead program MIV-818 can lean on such a solid intellectual property platform", says Dr. Uli Hacksell, CEO of Medivir.

For further information, please contact:

Uli Hacksell, CEO, Medivir AB, phone: +46(0)8-5468-3100.

About MIV-818

MIV-818 is a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug to benefit patients with HCC and other forms of liver cancer. A phase I study in patients with liver cancer is ongoing.

Danaher Reports Fourth Quarter and Full Year 2019 Results

On January 30, 2020 Danaher Corporation (NYSE: DHR) (the "Company") reported results for the fourth quarter and full year 2019 (Press release, Danaher, JAN 30, 2020, View Source [SID1234553727]). All results in this release reflect only continuing operations unless otherwise noted.

For the quarter ended December 31, 2019, net earnings were $792.9 million, or $1.07 per diluted share which represents a 11.5% year-over-year increase from the comparable 2018 period.

Non-GAAP adjusted diluted net earnings per share for the fourth quarter 2019 were $1.28 which represents a 12.5% increase over the comparable 2018 period. For the fourth quarter 2019, revenues increased 5.5% year-over-year to $4.9 billion, with non-GAAP core revenue growth of 6.0%.

For the full year 2019, net earnings were $2.4 billion, or $3.26 per diluted share which represents a 4.0% year-over-year decrease. Non-GAAP adjusted diluted net earnings per share for 2019 were $4.42 per share, which represents a 9.0% increase over the comparable 2018 amount. Revenues for the full year 2019 increased 5.0% to $17.9 billion, with non-GAAP core revenue growth of 6.0%.

For the first quarter 2020, the Company anticipates that diluted net earnings per share will be in the range of $0.78 to $0.81 and non-GAAP adjusted diluted net earnings per share will be in the range of $1.06 to $1.09.

For the full year 2020, the Company anticipates that diluted net earnings per share will be in the range of $3.96 to $4.06 and non-GAAP adjusted diluted net earnings per share will be $4.80 to $4.90, which assumes non-GAAP core revenue growth of approximately 5.0%. These first quarter and full year 2020 estimated results do not include the impact of earnings from the pending GE Biopharma acquisition, which is expected to close in the first quarter of 2020.

Thomas P. Joyce, Jr., President and Chief Executive Officer, stated, "Our fourth quarter results wrapped up a tremendous 2019 for Danaher. For the full year, we achieved 6.0% core revenue growth with solid margin expansion and cash flow. We continued to capture market share in many of our businesses through new product innovation and enhanced commercial execution. In addition, we completed the split-off of our Dental platform in December and announced the pending acquisition of GE’s Biopharma business."

Joyce added, "Through a combination of organic and inorganic initiatives, we have transformed Danaher into a higher growth, higher margin and higher recurring revenue company with leading positions in attractive end-markets. Our portfolio today -combined with the power of the Danaher Business System – positions us well to continue to deliver long-term shareholder value."

Danaher will discuss its results during its quarterly investor conference call today starting at 7:30 a.m. ET. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher’s website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Danaher’s website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 866-503-8675 within the U.S. or by dialing +1 786-815-8792 outside the U.S. a few minutes before the 7:30 a.m. ET start and telling the operator that you are dialing in for Danaher’s earnings conference call (access code 5867674). A replay of the conference call will be available shortly after the conclusion of the call and until February 13, 2020. You can access the replay dial-in information on the "Investors" section of Danaher’s website under the subheading "Events & Presentations." In addition, presentation materials relating to Danaher’s results have been posted to the "Investors" section of Danaher’s website under the subheading "Quarterly Earnings."

Neptune to Report Fiscal 2020 Third Quarter Financial Results on February 13, 2020

On January 30, 2020 Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ: NEPT) (TSX: NEPT), reported that it will report its financial results for the fiscal 2020 third quarter before financial markets open on February 13, 2020 (Press release, Neptune Technologies et Bioressources inc, JAN 30, 2020, View Source [SID1234553726]).

Following the release its financial results, the Company will host a conference call at 8:30 AM (EST) on February 13, 2020 to discuss the third quarter financial results for the three months period ended December 31, 2019.

Conference Call Details:

Date:

Thursday, February 13, 2020

Time:

8:30 AM Eastern Standard Time

Call:

1 (888) 231-8191 (Canada and U.S.)
1 (647) 427-7450 (International)

Conference ID: 8708188

A replay of the call will be available shortly after the call’s completion and until March 13, 2020. The replay can be accessed online in the Investors section of Neptune’s website under Investor Events and Presentations.